Type of preexisting lipid therapy predicts LDL-C response to ezetimibe

The Annals of Pharmacotherapy
Charles D MeyersNathan D Wong

Abstract

Ezetimibe as monotherapy or in combination with statins effectively lowers low-density lipoprotein cholesterol (LDL-C). However, there are few reports of ezetimibe's effect when added to ongoing non-statin lipid-lowering drugs or combination lipid-lowering therapy. To evaluate the impact of preexisting lipid therapy on LDL-C response to ezetimibe. We performed a retrospective review of all patients started on ezetimibe therapy at the Veterans Affairs Long Beach Healthcare System between March 1, 2003, and March 1, 2005. We calculated the ezetimibe-induced percent change in LDL-C in patients without concomitant changes in other lipid-lowering medications. We then stratified the population according to the type and number of preexisting lipid therapies and compared the LDL-C-lowering efficacy of ezetimibe among these groups. Overall, ezetimibe was associated with a 23.0% reduction in LDL-C. Patients with preexisting statin monotherapy had significantly greater LDL-C reduction with ezetimibe than did those with preexisting non-statin drugs (-26.1% vs -9.3%; p = 0.0138). In patients with no preexisting lipid therapy (n = 58), monotherapy (n = 115), double therapy (n = 36), or triple therapy (n = 9), ezetimibe decreased LDL-C by 17....Continue Reading

References

Nov 9, 2002·The American Journal of Cardiology·Claude GagnéUNKNOWN Ezetimibe Study Group
Feb 15, 2003·The American Journal of Cardiology·Boris KerznerUNKNOWN Ezetimibe Study Group
Nov 26, 2003·European Journal of Clinical Investigation·T A Miettinen, H Gylling
Mar 5, 2004·The American Journal of Cardiology·Javier JuradoPaul D Thompson
Sep 18, 2004·The American Journal of Cardiology·Antonios M XydakisChristie M Ballantyne
Mar 22, 2005·Atherosclerosis·Glenn M DaviesEnrico P Veltri
Mar 23, 2005·European Heart Journal·Michel FarnierUNKNOWN Ezetimibe Study Group
May 6, 2005·Clinical Pharmacokinetics·Teddy KosoglouKevin B Alton
Jun 2, 2005·Proceedings of the National Academy of Sciences of the United States of America·Margarita Garcia-CalvoNancy A Thornberry
Aug 27, 2005·European Heart Journal·Javier Borja

❮ Previous
Next ❯

Citations

Feb 16, 2010·European Journal of Pharmacology·Michalis KalogirouMoses Elisaf
Nov 16, 2006·Expert Opinion on Therapeutic Targets·Irene F Gazi, Dimitri P Mikhailidis

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.